Q-omics provides the consensus-scored ADAM3B profile across patient tissues and cancer cell-line models. ADAM3B expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ADAM3B is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, ADAM3B RNA expression shows 8,529 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight MESO, LUSC, and CCRCC as cancer lineages where ADAM3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAM3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAM3B survival associations across molecular data types. ADAM3B RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAM3B RNA expression–survival associations across cancer types. High ADAM3B expression shows unfavorable associations in MESO, CESC, LIHC, KIRP, COAD and STAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ADAM3B RNA expression.
This table summarizes ADAM3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ADAM3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAM3B shows lower tumor expression in LUSC, BRCA and KIRP and higher tumor expression in KICH and HNSC. The LUSC box plot shows higher ADAM3B RNA expression in normal versus tumor tissue (log2 FC = −0.026, t-test p < 0.001).
This table shows molecular features associated with ADAM3B in patient tissues and cancer cell lines. In patient samples, ADAM3B shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
